Ann: Chair Letter to Shareholders, page-10

if you’ve only researched Clinuvel for two days you’ll probably need to study a little bit longer. EPP is only the first orphan indication off the rank. With 40% yoy growth coupled with application for marketing to be submitted in Japan and Australia closely followed by XP and variagte porphyria indication extensions I don’t see $75mil sustained revenue being a problem. Add in vitiligo and the numbers are off the charts. Add in all dermatoses including Hailey-Hailey disease reaching large population numbers with reduced per unit price and we will have a monolithic company...